Arch Biopartners Inc.
ARCH.V
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.00% | -- | |||
| Cost of Revenue | -220.99% | -8.30% | |||
| Gross Profit | 220.45% | 134.62% | |||
| SG&A Expenses | 30.81% | -33.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -50.37% | -27.21% | |||
| Operating Income | 10.70% | 59.55% | |||
| Income Before Tax | -11.82% | 59.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.82% | 59.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.82% | 59.72% | |||
| EBIT | 10.70% | 59.55% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -15.38% | 60.61% | |||
| Normalized Basic EPS | -11.76% | 59.52% | |||
| EPS Diluted | -15.38% | 60.61% | |||
| Normalized Diluted EPS | -11.76% | 59.52% | |||
| Average Basic Shares Outstanding | -0.91% | 0.97% | |||
| Average Diluted Shares Outstanding | -0.91% | 0.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||